Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900671 | 0.89 | KMT2A (0.78) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL27910884 | 0.88 | KMT2A (0.77) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL12601787 | 0.85 | RAB9A (0.75) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL1673852 | 0.78 | KMT2A (0.64) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL28615396 | 0.78 | KMT2A (0.64) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL118567 | 0.78 | KMT2A (0.64) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL1260494 | 0.78 | KMT2A (0.64) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL28576782 | 0.78 | RAB9A (0.64) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL6468984 | 0.78 | RAB9A (0.64) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL2682787 | 0.78 | KMT2A (1.00) | KMT2APOLBNOTUMRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113307781-B | Synthesis method of 1,2, 3-thiadiazole derivative | 新疆大学 | 2024-07-02 | — | — | CN | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| CN-112778067-B | Method for synthesizing thioamide compound by catalyzing 1,2, 3-thiadiazole compound and amine with copper | 华南理工大学 | 2022-05-24 | — | — | CN | disclosed |
| CN-113307781-A | Synthetic method of 1,2,3-thiadiazole derivative | 新疆大学 | 2021-08-27 | — | — | CN | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-112778067-A | Method for synthesizing thioamide compound by using copper to catalyze 1,2, 3-thiodiazole compound and amine | 华南理工大学 | 2021-05-11 | — | — | CN | disclosed |
| EP-2623101-B1 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-10398749-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-10398680-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) | 2019-08-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-7160893-B2 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160893-B2 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2004101507-A2 | N-SULPHONYLATED AMINO ACID DERIVATIVES AND USE THEREOF AS MATRIPTASE INHIBITORS | CURACYTE CHEMISTRY GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | KMT2A 2101/4885POLB 3976/4885NOTUM 633/4885 |
| US-10398680-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | KMT2A 3360/4885POLB 1240/4885NOTUM 3363/4885 |
| US-10398749-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | KMT2A 3360/4885POLB 1240/4885NOTUM 3363/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | KMT2A 4180/4885POLB 1121/4885NOTUM 1/4885 |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | KMT2A 875/4885POLB 3621/4885NOTUM 1783/4885 |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | KMT2A 3360/4885POLB 1240/4885NOTUM 3363/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | KMT2A 3672/4885POLB 1592/4885NOTUM 5/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | KMT2A 700/4885POLB 1433/4885NOTUM 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.